Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary R Matyas

Showing results (101-110 of 120) with videos related to

Pageof 12
Sort By:
NPJ Vaccines|April 10, 2021
Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primatesKevin O Saunders, Norbert Pardi, Robert Parks, et al.
NPJ Vaccines|November 7, 2021
Author Correction: Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primatesKevin O Saunders, Norbert Pardi, Robert Parks, et al.
NPJ Vaccines|March 19, 2023
SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodiesShikha Shrivastava, Joshua M Carmen, Zhongyan Lu, et al.
Plos Pathogens|September 4, 2020
Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challengeKier Om, Dominic Paquin-Proulx, Maria Montero, et al.
Journal of Virology|May 15, 2015
Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine ResearchLindsay Wieczorek, Shelly J Krebs, Vaniambadi Kalyanaraman, et al.
The Lancet. Microbe|May 18, 2024
SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trialBrittany L Ober Shepherd, Paul T Scott, Jack N Hutter, et al.
NPJ Vaccines|December 19, 2025
ALFQ adjuvanted HIV-1 envelope protein vaccination elicits durable functional antibody and cellular responses in nonhuman primatesShikha Shrivastava, Joshua M Carmen, Jiae Kim, et al.
Vaccines|October 28, 2025
Production of Clinical-Grade SARS-CoV-2 Spike Ferritin Nanoparticle Protein Immunogen by Transient TransfectionAgnes Hajduczki, William C Chang, Rafael De La Barrera, et al.
Cell Reports. Medicine|April 6, 2023
Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaquesJingyou Yu, Paul V Thomas, Michaela Sciacca, et al.
Science Advances|November 23, 2022
Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFNJingyou Yu, Paul V Thomas, Katherine McMahan, et al.
Pageof 12

Showing results (101-110 of 120) with videos related to

Sort By:
Pageof 12
NPJ Vaccines|April 10, 2021
Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primatesKevin O Saunders, Norbert Pardi, Robert Parks, et al.
NPJ Vaccines|November 7, 2021
Author Correction: Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primatesKevin O Saunders, Norbert Pardi, Robert Parks, et al.
NPJ Vaccines|March 19, 2023
SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodiesShikha Shrivastava, Joshua M Carmen, Zhongyan Lu, et al.
Plos Pathogens|September 4, 2020
Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challengeKier Om, Dominic Paquin-Proulx, Maria Montero, et al.
Journal of Virology|May 15, 2015
Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine ResearchLindsay Wieczorek, Shelly J Krebs, Vaniambadi Kalyanaraman, et al.
The Lancet. Microbe|May 18, 2024
SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trialBrittany L Ober Shepherd, Paul T Scott, Jack N Hutter, et al.
NPJ Vaccines|December 19, 2025
ALFQ adjuvanted HIV-1 envelope protein vaccination elicits durable functional antibody and cellular responses in nonhuman primatesShikha Shrivastava, Joshua M Carmen, Jiae Kim, et al.
Vaccines|October 28, 2025
Production of Clinical-Grade SARS-CoV-2 Spike Ferritin Nanoparticle Protein Immunogen by Transient TransfectionAgnes Hajduczki, William C Chang, Rafael De La Barrera, et al.
Cell Reports. Medicine|April 6, 2023
Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaquesJingyou Yu, Paul V Thomas, Michaela Sciacca, et al.
Science Advances|November 23, 2022
Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFNJingyou Yu, Paul V Thomas, Katherine McMahan, et al.
Pageof 12